Psychiatric services and prescription fills among veterans with serious mental illness in methadone maintenance treatment

Journal of Dual Diagnosis

Volumn 11, Issue 2, 2015, Pages 128-135

  Marienfeld, Carla ^a   Rosenheck, Robert A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Center   (United States)

Author keywords

Methadone; Severe mental illness; Veterans' Health Administration

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; LITHIUM; METHADONE; MOOD STABILIZER; NEUROLEPTIC AGENT; SEDATIVE AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; COMPARATIVE STUDY; DRUG ABUSE; FEMALE; HEALTH CARE MANAGEMENT; HEALTH SERVICE; HUMAN; ICD-9; MAJOR AFFECTIVE DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL HEALTH; MENTAL HEALTH SERVICE; MENTAL PATIENT; METHADONE TREATMENT; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; SCHIZOPHRENIA; SUBSTANCE ABUSE; URBAN AREA; VETERAN; VETERANS HEALTH; GOVERNMENT; MENTAL DISORDERS; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84929669331     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1080/15504263.2015.1025024     Document Type: Article

References (25)

1. Anglin, M. D., Speckart, G. R., Booth, M. W., & Ryan, T. M. (1989). Consequences and costs of shutting off methadone. Addictive Behaviors, 14(3), 307-326.
2. Bogenschutz, M. P., & Siegfreid, S. L. (1998). Factors affecting engagement of dual diagnosis patients in outpatient treatment. Psychiatric Services, 49(10), 1350-1352.
3. Brooner, R. K., King, V. L., Kidorf, M., Schmidt, C. W., & Bigelow, G. E. (1997). Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry, 54(1), 71-80.
4. Brunette, M. F., & Mueser, K. T. (2006). Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. Journal of Clinical Psychiatry, 67(Suppl 7), 10-17.
5. Centorrino, F., Hernán, M. A., Drago-Ferrante, G., Rendall, M., Apicella, A., Längar, G., & Baldessarini, R. J. (2001). Factors associated with noncompliance with psychiatric outpatient visits. Psychiatric Services, 52(3), 378-380. doi:10. 1176/appi. ps. 52. 3. 378
6. Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373-383.
7. Dole, V. P., Robinson, J. W., Orraca, J., Towns, E., Searcy, P., & Caine, E. (1969). Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine, 280(25), 1372-1375. doi:10. 1056/NEJM196906192802502
8. Doran, K. M., Raven, M. C., & Rosenheck, R. A. (2013). What drives frequent emergency department use in an integrated health system? National data from the Veterans Health Administration. Annals of Emergency Medicine, 62(2), 151-159. doi:10. 1016/j. annemergmed. 2013. 02. 016
9. Drake, R. E., Essock, S. M., Shaner, A., Carey, K. B., Minkoff, K., Kola, L., Rickards, L. (2001). Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52(4), 469-476. doi:10. 1176/appi. ps. 52. 4. 469
10. Evans, J. L., Tsui, J. I., Hahn, J. A., Davidson, P. J., Lum, P. J., & Page, K. (2012). Mortality among young injection drug users in San Francisco: A 10-year follow-up of the UFO study. American Journal of Epidemiology, 175(4), 302-308. doi:10. 1093/aje/kwr318
11. Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services, 65(2), 146-157. doi:10. 1176/appi. ps. 201300235
12. Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Kaplan, K. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 61(8), 807-816. doi:10. 1001/archpsyc. 61. 8. 807
13. Gruber,V. A., & McCance-Katz, E. F. (2010). Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Current HIV/AIDS Reports, 7(3), 152-160. doi:10. 1007/s11904-010-0048-2
14. Hser, Y. I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of narcotics addicts. Archives of General Psychiatry, 58(5), 503-508. doi:10. 1001/archpsyc. 58. 5. 503
15. Macarthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., Hickman, M. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ, 345, e5945. doi:10. 1136/bmj. e5945
16. Marienfeld, C., & Rosenheck, R. (2013). National psychotropic prescription dispensation among dually diagnosed patients. Advances in Dual Diagnosis, 6(1), 34-44. doi:10. 1108/17570971311309015
17. Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews, 3, CD002209. doi:10. 1002/14651858. CD002209. pub2
18. McCance-Katz,E. F., Sullivan,L. E., & Nallani,S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. The American Journal on Addictions, 19(1), 4-16. doi:10. 1111/j. 1521-0391. 2009. 00005. x
19. Olfson, M., Mechanic, D., Hansell, S., Boyer, C. A., Walkup, J., & Weiden, P. J. (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services, 51(2), 216-222. doi:10. 1176/appi. ps. 51. 2. 216
20. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487-497. doi:/NEJMra050100
21. Ryan, C. F., & White, J. M. (1996). Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction, 91(1), 39-45.
22. Teter, C. J., Falone, A. E., Bakaian, A. M., Tu, C., Ongur, D., & Weiss, R. D. (2011). Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. Psychiatry Research, 190(2-3), 253-258. doi:10. 1016/j. psychres. 2011. 05. 042
23. Van Den Berg, C., Smit, C., Van Brussel, G., Coutinho, R., Prins, M., & Cohort, A. (2007). Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction, 102(9), 1454-1462. doi:10. 1111/j. 1360-0443. 2007. 01912. x
24. Weisner, C., Mertens, J., Parthasarathy, S., Moore, C., & Lu, Y. (2001). Integrating primary medical care with addiction treatment: A randomized controlled trial. JAMA: The Journal of the American Medical Association, 286(14), 1715-1723. doi:10. 1001/jama. 286. 14. 1715
25. Wolpe, P. R., Gorton, G., Serota, R., & Sanford, B. (1993). Predicting compliance of dual diagnosis inpatients with aftercare treatment. Hospital & Community Psychiatry, 44(1), 45-49.